EluNIR is Medinol’s sixth generation coronary stent featuring a unique stent design which utilizes a distinctive CoCr framework composed of alternate strut widths, uniformly coated with an elastomeric coating and a Rapamycin analog drug. This combination ensures consistent drug elution and structural integrity. The EluNIR has been studied in thousands of patients demonstrating outstanding clinical results.
Key Features
Superior Deliverability
Superior deliverability with a unique radiopaque spring metal tipOptimal Flexibility
Unique stent design providing optimal flexibility and radial strength resulting in superior scaffolding and vessel conformability
Outstanding Surface Integrity
Elastomeric coating and outstanding surface integrity providing a uniform limus analogue drug elution
Clinical Overview
5.4%
n=958
Target Lesion Failure
1-yr BIONICS trial results
0.4%
n=958
Stent Thrombosis (Definite+Probable)
1-yr BIONICS trial results
3.2%
n=958
Target Vessel Myocardial Infraction
1-yr BIONICS trial results
EluNIR DES
Testimonials
Major Regulatory Approvals
FDA
CE Mark
PMDA
KFDA
ANVISA
